(Q42954066)

11 November 2017

title

Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma (English)

1 reference

11 November 2017

Phase 1 trial of bortezomib plus R‐CHOP in previously untreated patients with aggressive non‐Hodgkin lymphoma (English)

1 reference

12 June 2024

main subject

phase I clinical trial

0 references

5

Julie M Vose

1 reference

11 November 2017

6

Ann S LaCasce

1 reference

11 November 2017

Peter Martin

2

1 reference

11 November 2017

Jia Ruan

3

1 reference

11 November 2017

Rebecca Elstrom

7

1 reference

11 November 2017

Morton Coleman

8

1 reference

11 November 2017

Richard R. Furman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665890

12 June 2024

Ying-Kuen K. Cheung

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665890

12 June 2024

John P. Leonard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665890

12 June 2024

language of work or name

English

0 references

publication date

27 July 2010

1 reference

11 November 2017

number of pages

8

1 reference

full work available at URL

inferred from page(s)

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.25509

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665890

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25509

12 June 2024

1 reference

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25509/fullpdf

12 June 2024

1 reference

12 June 2024

1 reference

11 November 2017

volume

116

1 reference

11 November 2017

issue

23

1 reference

11 November 2017

page(s)

5432-5439

1 reference

Mechanisms of B-cell lymphoma pathogenesis

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

State-of-the-art therapeutics: diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

CHOP plus rituximab--balancing facts and opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

The continual reassessment method in cancer phase I clinical trials: a simulation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

Treatment of non-Hodgkin's lymphoma: a look over the past decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

7 January 2021

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

7 January 2021

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

7 January 2021

Sequential designs for phase I clinical trials with late-onset toxicities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

7 January 2021

A simple technique to evaluate model sensitivity in the continual reassessment method

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

7 January 2021

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25509

7 January 2021

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

34

1 reference

12 June 2024

Identifiers

DOI

10.1002/CNCR.25509

1 reference

11 November 2017

1 reference